GENE ONLINE|News &
Opinion
Blog

2022-04-22| Licensing

Emerging NY Biotech Furthers Sanofi’s CNS Therapeutics

by Fujie Tham
Share To

A novel New York-based biotech managed to impress Sanofi, snatching a deal to obtain two Phase III CNS pipelines. In a brief press release, not much was disclosed about the scope of the deal, it included an upfront payment, but specific financial details of the deal were not revealed.

Terran Biosciences, dedicated to the development of transformational therapeutics for neurological diseases, secured the agreement with Sanofi for exclusive global rights to develop and market said two late-stage CNS assets. These therapeutics generated 4 Investigational New Drug (IND) applications and more than 104 clinical studies involving over 15,000 subjects across numerous CNS indications.

Terran plans to rapidly advance development of these new pipelines for neurological and psychiatric indications with novel applications for large unmet medical demands. This transaction represents a major next stage in the development of these promising portfolios.

“We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry,” said Dr. Sam Clark, Terran’s Founder and CEO.

Related Article: Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

 

Mysterious NY Biotech

 

Equipped with a bare corporate webpage, little is known about Terran Biosciences. Known investors include Noetic Fund and Catalytic Impact Foundation. The biotech also popped up in March recently to sign a CNS “portfolio” and intellectual properties deal with Concert.

Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing a number of late-stage assets, which include novel psychedelic-based therapeutics.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
2022-11-09
Sanofi, miRecule To Develop Muscular Dystrophy Candidate In $400+ Million Partnership
2022-10-05
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!